Document Detail

Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
MedLine Citation:
PMID:  19927151     Owner:  NLM     Status:  MEDLINE    
In general, treatment with most angiotensin receptor blockers (ARBs) increases plasma angiotensin II (Ang II) level because of a lack of negative feedback on renin activity. Olmesartan is a potential ARB inducing activation of angiotensin-converting enzyme 2 (ACE2) that hydrolyzes Ang II to Ang 1-7, and has shown a beneficial effect on ventricular remodeling. Indeed, a previous study reported that olmesartan treatment resulted in decreased plasma levels of Ang II and aldosterone. However, there has not yet been a study showing the relationship of chronic effects of olmesartan on Ang II and the left ventricular mass index (LVMI) in comparison with those of other ARB.A total of 50 stable outpatients with essential hypertension who had received candesartan for more than 1 year were randomized into two groups: control group (n=25): continuous candesartan treatment at a stable dose; and olmesartan group (n=25): candesartan (8 mg day(-1)) was changed to olmesartan given at a dose of 20 mg day(-1). There was no difference in the baseline characteristics between the two groups. In the control group, there were no significant changes in blood pressure, LVMI or biomarkers during 12 months of study. In the olmesartan group, blood pressure did not change and plasma levels of Ang II decreased during 12 months of study, whereas LVMI was significantly decreased after 12 months (135+/-36 vs. 123+/-29 g m(-2); P<0.01).These findings indicate that replacing candesartan with olmesartan decreased LVMI in association with a sustained decrease of plasma Ang II over a 12-month period without changing blood pressure or plasma aldosterone in patients with essential hypertension.
Takayoshi Tsutamoto; Keizo Nishiyama; Masayuki Yamaji; Chiho Kawahara; Masanori Fujii; Takashi Yamamoto; Minoru Horie
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial     Date:  2009-11-20
Journal Detail:
Title:  Hypertension research : official journal of the Japanese Society of Hypertension     Volume:  33     ISSN:  1348-4214     ISO Abbreviation:  Hypertens. Res.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-08     Completed Date:  2010-04-21     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9307690     Medline TA:  Hypertens Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  118-22     Citation Subset:  IM    
Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aldosterone / blood
Angiotensin II / blood*
Angiotensin II Type 1 Receptor Blockers / pharmacology*
Antihypertensive Agents / pharmacology*
Benzimidazoles / pharmacology*
Hypertension / blood,  drug therapy*
Hypertrophy, Left Ventricular / prevention & control*
Imidazoles / pharmacology*
Middle Aged
Natriuretic Peptide, Brain / blood
Peptidyl-Dipeptidase A / genetics
Tetrazoles / pharmacology*
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Imidazoles; 0/Tetrazoles; 11128-99-7/Angiotensin II; 114471-18-0/Natriuretic Peptide, Brain; 52-39-1/Aldosterone; 8W1IQP3U10/olmesartan; EC A; EC 3.4.17.-/angiotensin converting enzyme 2; S8Q36MD2XX/candesartan
Comment In:
Hypertens Res. 2010 Feb;33(2):105-6   [PMID:  19942930 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Renal ACE2 expression and activity is unaltered during established hypertension in adult SHRSP and T...
Next Document:  Accumulation of common polymorphisms is associated with development of hypertension: a 12-year follo...